NeuroSense Targets December 2026 NDS Filing for ALS Drug PrimeC After Health Canada Alignment
Event summary
- NeuroSense aims to file a New Drug Submission (NDS) for PrimeC with Health Canada by December 2026, following alignment on submission content and structure.
- Health Canada has no concerns with the proposed filing timeline and advised targeting early December.
- PrimeC's NDS will be supported by Phase 2b PARADIGM clinical program data, including a ~15-month median survival benefit (HR 0.35, p=0.0037).
- NeuroSense is progressing the Canadian NDS in parallel with preparations for its confirmatory Phase 3 PARAGON study.
The big picture
NeuroSense's strategic move to file an NDS for PrimeC in Canada underscores the critical need for effective ALS therapies, given the limited treatment options and high healthcare burden. The alignment with Health Canada positions NeuroSense to potentially bring a promising therapy to market, while the ongoing Phase 3 PARAGON study could further validate PrimeC's clinical benefits.
What we're watching
- Regulatory Approval Timing
- Whether Health Canada will accept and review the NDS within its target 300-day timeline following acceptance.
- Clinical Trial Progress
- The pace at which NeuroSense advances its confirmatory Phase 3 PARAGON study in parallel with the Canadian NDS.
- Market Potential
- How PrimeC's potential approval and commercialization will address the substantial unmet medical need for ALS treatments in Canada.
Related topics